Proprietary Pipeline

Candidate
& Indication
LEAD CANDIDATE:
TRIOZAN™/siRNA Gal-1 (checkpoint inhibitor combination regimen)
► Cancer (Head & Neck)
Discovery
Research		 Candidate
Optimization		 Preclinical Clinical

Collaborations

Program Partner
TRIOZAN™/mAb
► Central Nervous System
Discovery
Research		 Candidate
Optimization

DEVELOPMENT

Ovensa is currently advancing the development of its TRIOZAN™/siRNA Gal-1 lead candidate to be used in a combination regimen with an anti-PD-1 checkpoint inhibitor in head & neck cancer as a first indication.

PARTNERSHIP

Ovensa is welcoming strategic partnerships with pharmaceutical companies to develop precision and combination medicine therapeutics through its TRIOZAN™ Platform for specific indications.

Proprietary Pipeline

Candidate
& Indication
LEAD CANDIDATE:
TRIOZAN™/siRNA Gal-1
(checkpoint inhibitor
combination regimen)
► Cancer (Head & Neck)
Candidate Optimization

Collaborations

Program
TRIOZAN™/mAb
► Central Nervous
► System
Partner:
Discovery Research
Program
TRIOZAN™/Cannabinoids
► Glioblastoma
► Multiforme
Partner:
Discovery Research

DEVELOPMENT

Ovensa is currently advancing the development of its TRIOZAN™/siRNA Gal-1 lead candidate to be used in a combination regimen with an anti-PD-1 checkpoint inhibitor in head & neck cancer as a first indication.

PARTNERSHIP

Ovensa is welcoming strategic partnerships with pharmaceutical companies to develop precision and combination medicine therapeutics through its TRIOZANTM Platform for specific indications.